dm+d

Unassigned

New Medicines

TonmyaFibromyalgia - very low dose for chronic daily use

Information

Tonmya
New molecular entity
Not Known
Tonix Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Central reduction of tonic somatic motor activity - TNX 102 aims to improve sleep quality to reduce pain and other symptoms of fibromyalgia
It is thought that the condition is common and under diagnosed. The estimated prevalence in North America and Europe is as high as 5.8%. Women are 10 times more commonly affected than men [1].
Fibromyalgia - very low dose for chronic daily use
Sublingual

TonmyaPost-traumatic stress disorder (PTSD) - very low dose formulation

Information

Tonmya
New molecular entity
Not Known
Tonix Pharmaceuticals

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 20Cyclobenzaprine (TNX-102) for PTSD no longer listed in company pipeline; assume development discontinued after it failed to demonstrate a statistically significant improvement of overall change from baseline in the severity of PTSD symptoms, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) in the PIII RECOVERY trial [14].

Category

Central reduction of tonic somatic motor activity . Eutectic formulation of cyclobenzaprine for under-the-tongue administration allows transmucosal absorption of cyclobenzaprine, which bypasses first pass liver metabolism.
Post-traumatic stress disorder is common among armed forces veterans and other military personnel, and also occurs in the non-military population. PTSD can arise from witnessing or experiencing traumatic events, and is linked to impulsive violent or reckless behaviors as well as suicide. An estimated 3.5% of American adults, or approximately 8.5 million individuals, suffer from PTSD each year, and only about half of these are receiving some form of treatment [1].
Post-traumatic stress disorder (PTSD) - very low dose formulation
Sublingual